$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

$atos Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-Q Financial Statement

#000143774920023747 Filed on November 13, 2020

Income Statement

Concept	2020 Q3	2019 Q3	2019 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.850M	$1.610M	$4.670M
YoY Change	14.91%	-14.81%	74.91%
% of Gross Profit
Research & Development	$1.659M	$1.684M	$2.612M
YoY Change	-1.49%	18.45%	77.96%
% of Gross Profit
Depreciation & Amortization	$20.00K	$10.00K	$20.00K
YoY Change	100.0%	0.0%	100.0%
% of Gross Profit
Operating Expenses	$3.509M	$3.298M	$7.286M
YoY Change	6.39%	-0.36%	75.88%
Operating Profit	-$3.509M	-$3.298M	-$7.286M
YoY Change	6.39%	-0.36%	75.88%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$17.75K	$12.28K	$23.54K
YoY Change	44.46%	11711.54%	29697.47%
Pretax Income	-$3.491M	-$3.286M	-$7.263M
YoY Change	6.24%	-0.72%	75.31%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$3.491M	-$3.286M	-$7.263M
YoY Change	6.24%	-0.72%	75.31%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$343.5K	-$360.4K	-$795.2K
COMMON SHARES
Basic Shares Outstanding	10.40M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q3	2019 Q3	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.100M	$15.30M	$17.10M
YoY Change	-40.52%	18.6%	12.5%
Cash & Equivalents	$9.106M	$15.29M	$17.06M
Short-Term Investments
Other Short-Term Assets	$178.9K	$2.064K	$140.00
YoY Change	8568.17%	-98.72%	-99.97%
Inventory
Prepaid Expenses	$1.484M	$430.0K	$813.2K
Receivables
Other Receivables
Total Short-Term Assets	$11.32M	$16.40M	$18.39M
YoY Change	-30.99%	17.8%	12.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.43K	$39.14K	$44.17K
YoY Change	-35.03%	-32.28%	-55.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$17.22K	$17.22K	$17.22K
YoY Change	0.0%	-80.55%
Total Long-Term Assets	$119.3K	$195.9K	$221.2K
YoY Change	-39.08%	-2.75%	10.59%
TOTAL ASSETS
Total Short-Term Assets	$11.32M	$16.40M	$18.39M
Total Long-Term Assets	$119.3K	$195.9K	$221.2K
Total Assets	$11.44M	$16.60M	$18.61M
YoY Change	-31.08%	17.5%	12.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$682.6K	$501.4K	$318.3K
YoY Change	36.13%	-8.95%	59.13%
Accrued Expenses	$85.17K	$225.5K	$53.49K
YoY Change	-62.22%	336.34%	-95.54%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.565M	$1.564M	$1.033M
YoY Change	0.07%	-56.0%	-65.57%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.565M	$1.564M	$1.033M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.567M	$1.578M	$1.057M
YoY Change	-0.74%	-56.16%	-64.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$104.4M	-$91.45M	-$88.17M
YoY Change	14.17%	22.34%
Common Stock	$113.7M	$105.8M	$105.0M
YoY Change	7.43%	29.33%
Preferred Stock		$671.0K	$676.0K
YoY Change		-80.92%
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.871M	$15.02M	$17.55M
YoY Change
Total Liabilities & Shareholders Equity	$11.44M	$16.60M	$18.61M
YoY Change	-31.08%	17.5%	12.1%

Cashflow Statement

Concept	2020 Q3	2019 Q3	2019 Q2
OPERATING ACTIVITIES
Net Income	-$3.491M	-$3.286M	-$7.263M
YoY Change	6.24%	-0.72%	75.31%
Depreciation, Depletion And Amortization	$20.00K	$10.00K	$20.00K
YoY Change	100.0%	0.0%	100.0%
Cash From Operating Activities	-$2.680M	-$1.770M	-$2.500M
YoY Change	51.41%	-23.04%	36.61%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$10.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.320M	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-2.680M	-1.770M	-2.500M
Cash From Investing Activities	0.000	0.000	-10.00K
Cash From Financing Activities	4.320M	0.000	0.000
Net Change In Cash	1.640M	-1.770M	-2.510M
YoY Change	-192.66%	-23.04%	-124.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.680M	-$1.770M	-$2.500M
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$2.680M	-$1.770M	-$2.490M
YoY Change	51.41%	-23.04%	36.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	atos	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	2800000
CY2019Q3	atos	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	0
CY2020Q2	atos	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	20200
CY2020Q2	atos	Increase Decrease In Operating Lease Right Of Use Asset And Liability IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiability	20200
	atos	Increase Decrease In Research And Development Tax Rebate Receivable IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable	-300451
	atos	Increase Decrease In Research And Development Tax Rebate Receivable IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable	50882
CY2020Q3	atos	Number Of Shares Authorized To Issue NumberOfSharesAuthorizedToIssue	185000000
CY2019Q1	atos	Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation	3151944
CY2019Q1	atos	Adjustments To Additional Paid In Capital Transfer Of Stockbased Compensation Liability Upon Option Cancellation AdjustmentsToAdditionalPaidInCapitalTransferOfStockbasedCompensationLiabilityUponOptionCancellation	3151944
	atos	Change In Stock Based Compensation Liability ChangeInStockBasedCompensationLiability
	atos	Change In Stock Based Compensation Liability ChangeInStockBasedCompensationLiability	1741919
CY2020Q3	atos	Prepaid Financial Exchange Fees Current PrepaidFinancialExchangeFeesCurrent	10750
CY2019Q4	atos	Prepaid Financial Exchange Fees Current PrepaidFinancialExchangeFeesCurrent
	atos	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	4686298
	atos	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet
CY2020Q3	atos	Professional Services Current ProfessionalServicesCurrent	199002
CY2019Q4	atos	Professional Services Current ProfessionalServicesCurrent	108850
	atos	Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation
	atos	Reclassification Of Stock Based Liability Awards To Equity Upon Cancellation ReclassificationOfStockBasedLiabilityAwardsToEquityUponCancellation	3151944
CY2020Q3	atos	Research And Development Current ResearchAndDevelopmentCurrent	1176042
CY2019Q4	atos	Research And Development Current ResearchAndDevelopmentCurrent	507733
CY2020Q3	atos	Research And Development Tax Rebate Receivable ResearchAndDevelopmentTaxRebateReceivable	439205
CY2019Q4	atos	Research And Development Tax Rebate Receivable ResearchAndDevelopmentTaxRebateReceivable	739656
	atos	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeitures In Period Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue	272000
	atos	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	449600
	atos	Stock Issued During Period Shares Warrant Exercised StockIssuedDuringPeriodSharesWarrantExercised	2800000
CY2020Q3	atos	Stock Repurchased During Period For Stock Option Exercise And Taxes Value StockRepurchasedDuringPeriodForStockOptionExerciseAndTaxesValue	555522
CY2020Q3	atos	Working Capital WorkingCapital	9800000
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85173
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	77888
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	275833
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	682612
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5318796
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	293171
CY2020Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	498359
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	751652
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	646064
CY2020Q3	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	0
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	687752
CY2019Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	0
CY2020Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	91690
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	82536
CY2020Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	162798
CY2019Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	170820
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	111780197
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	104912480
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1036484
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	663593
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	135157
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	663593
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	751652
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2387829
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6346281
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8405977
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15399543
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3475186
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4909050
CY2020Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	8032950
CY2019Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	12316429
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9105950
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15289543
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12581136
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12691136
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10490493
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9215950
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7078654
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5609954
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4681513
CY2020Q3	us-gaap	Assets Assets	11437660
CY2019Q4	us-gaap	Assets Assets	14489855
CY2020Q3	us-gaap	Assets Current AssetsCurrent	11318317
CY2019Q4	us-gaap	Assets Current AssetsCurrent	14319266
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.18
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10464250
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9130984
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10464250
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9130984
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	1883553
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1643565
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	48000
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1707999
CY2020Q3	us-gaap	Deposit Assets DepositAssets	14218
CY2019Q4	us-gaap	Deposit Assets DepositAssets	14218
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	37265
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	40289
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-4149
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-5806
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.09
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.77
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	752847
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	899420
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	45417
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	68542
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1849741
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1613983
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6130698
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8901197
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3491071
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3285914
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10344633
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14621750
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	389441
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	148102
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7285
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-165343
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-146573
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	48398
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	152781
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-28878
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1779
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-21524
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	621907
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-79791
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19400
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	14200
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2300
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13000
CY2020Q3	us-gaap	Liabilities Liabilities	1566583
CY2019Q4	us-gaap	Liabilities Liabilities	1333850
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11437660
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14489855
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1565366
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1322742
	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font: inherit;">1:</div> NATURE OF OPERATIONS</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> January 6, 2020, </div>we changed our corporate name from Atossa Genetics Inc. to Atossa Therapeutics, Inc.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">Atossa Therapeutics, Inc. (the “Company”) was incorporated on <div style="display: inline; font-style: italic; font: inherit;"> April 30, 2009, </div>in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company's fiscal year ends on <div style="display: inline; font-style: italic; font: inherit;"> December 31. </div>The Company is currently focused on development of its pharmaceuticals for the treatment of the novel coronavirus ("COVID-<div style="display: inline; font-style: italic; font: inherit;">19"</div>), breast cancer and other breast conditions.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 21.45pt 0pt -9pt; text-align: justify; text-indent: 18pt;"><div style="display: inline; font-weight: bold;">Impact of the Novel Coronavirus </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -9pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">The continued spread of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is affecting the United States and global economies and <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the Company's operations and those of <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which the Company relies, including causing possible disruptions in the supply of the Company's Endoxifen, AT-<div style="display: inline; font-style: italic; font: inherit;">H201,</div> AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> and the conduct of current and future clinical trials. In addition, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the operations of the U.S. Food and Drug Administration and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. The evolving COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic could also directly or indirectly impact the pace of enrollment in the Company's clinical trials for at least the next several months and possibly longer as patients <div style="display: inline; font-style: italic; font: inherit;"> may </div>avoid or <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be able to travel to healthcare facilities and physicians' offices except for a health emergency. Such facilities and offices <div style="display: inline; font-style: italic; font: inherit;"> may </div>also be required to focus limited resources on non-clinical trial activities, including treatment of COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> patients, and <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be available, in whole or in part, for clinical trial activities related to the Company's products under development. Additionally, while the potential economic impact brought by, and the duration of, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is difficult to assess or predict, the impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic on the global financial markets <div style="display: inline; font-style: italic; font: inherit;"> may </div>reduce the Company's ability to access capital, which could negatively impact the Company's short-term and long-term liquidity. The ultimate impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is highly uncertain and subject to change. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> yet know the full extent of potential delays or impacts on its business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on the Company's liquidity, capital resources, operations, financial position and business and those of the <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which we rely. As of <div style="display: inline; font-style: italic; font: inherit;"> September </div><div style="display: inline; font-style: italic; font: inherit;">30,</div> <div style="display: inline; font-style: italic; font: inherit;">2020,</div> the Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any delay in drug supply for its ongoing and planned clinical studies, including studies of Endoxifen, AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> and AT-<div style="display: inline; font-style: italic; font: inherit;">H201.</div> Currently, enrollment is open in Australia for the Endixofen Window of Opportunity study for which enrollment continues to be slow due in part to disruption caused by COVID-<div style="display: inline; font-style: italic; font: inherit;">19.</div> The Company anticipates commencing the Mammographic Breast Density (“MBD”) Endoxifen trial in the <div style="display: inline; font-style: italic; font: inherit;">fourth</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020.</div> The Company opened enrollment in the AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> trial during the <div style="display: inline; font-style: italic; font: inherit;">third</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020</div> and completed enrollment in the <div style="display: inline; font-style: italic; font: inherit;">fourth</div> quarter <div style="display: inline; font-style: italic; font: inherit;">2020.</div> We anticipate receiving regulatory approval to commence the initial clinical study of <div style="display: inline; font-style: italic; font: inherit;">one</div> of the components of AT-<div style="display: inline; font-style: italic; font: inherit;">H201</div> in the <div style="display: inline; font-style: italic; font: inherit;">first</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2021.</div> The Company will continue to monitor future enrollment in studies for potential restrictions on site visits, mammograms or the impositions of new restrictions on trials as a result of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;">In response to the Coronavirus pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on <div style="display: inline; font-style: italic; font: inherit;"> March 27, 2020.  </div>The CARES Act, among other things, includes provisions related to refundable payroll tax credits, deferment of employer side social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.  The CARES Act had <div style="display: inline; font-style: italic; font: inherit;">no</div> material impact on the Company's income tax provision for the <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">nine</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> September </div><div style="display: inline; font-style: italic; font: inherit;">30,</div> <div style="display: inline; font-style: italic; font: inherit;">2020.</div>  The Company continues to examine the elements of the CARES Act and the impact it <div style="display: inline; font-style: italic; font: inherit;"> may </div>have on its financial position, results of operations and cash flows.</div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4671876
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11336710
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9367
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7625
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8137695
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6420035
	us-gaap	Net Income Loss NetIncomeLoss	-10344633
	us-gaap	Net Income Loss NetIncomeLoss	-14621750
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3491071
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-3285914
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4073307
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-7262529
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2947420
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-3906142
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3491071
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3285914
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10344633
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14621750
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	3508816
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	3298198
	us-gaap	Operating Expenses OperatingExpenses	10381632
	us-gaap	Operating Expenses OperatingExpenses	14648596
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3508816
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10381632
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3298198
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12892
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17745
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1659075
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1684215
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4250934
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5747399
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14648596
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	14200
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	14700
	us-gaap	Operating Lease Expense OperatingLeaseExpense	46300
	us-gaap	Operating Lease Expense OperatingLeaseExpense	44100
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	30063
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39371
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1217
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11108
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	12900
	us-gaap	Operating Lease Payments OperatingLeasePayments	42300
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	13900
	us-gaap	Operating Lease Payments OperatingLeasePayments	42700
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31279
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50479
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.113
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y
CY2020Q3	us-gaap	Other Assets Current OtherAssetsCurrent	178911
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	26130
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17218
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17218
CY2020Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	14671
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12284
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	36999
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	26846
CY2020Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	11560
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4792
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14422
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9367
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7625
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	623
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	671
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	623
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	671
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	1
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	1
CY2020Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1484251
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	862344
CY2020Q3	us-gaap	Prepaid Insurance PrepaidInsurance	63703
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	222476
CY2020Q3	us-gaap	Prepaid Rent PrepaidRent	8976
CY2019Q4	us-gaap	Prepaid Rent PrepaidRent	4275
CY2020Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11300000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11336710
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25429
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34350
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	110000
CY2020Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	110000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	110000
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104415673
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94071040
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y310D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y310D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	670000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4332821
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.34
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	297250
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	143552
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3140000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	651000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5629600
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4308383
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7079831
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.44
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.77
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5629600
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7079831
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.77
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.40
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.87
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.79
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3616727
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y153D
	us-gaap	Stock Issued1 StockIssued1	541100
	us-gaap	Stock Issued1 StockIssued1
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	225000
CY2019Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2019Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2019Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2020Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2020Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	347627
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4338671
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	541100
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2387829
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	6346281
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	8805010
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	19496190
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	17552457
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	15018195
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	13156005
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	10896337
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	8374306
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	9871077
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div>
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10162770
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9130057
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9496222
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8283302

Files In Submission

Name	View Source	Status
0001437749-20-023747-index-headers.html	Edgar Link	pending
0001437749-20-023747-index.html	Edgar Link	pending
0001437749-20-023747.txt	Edgar Link	pending
0001437749-20-023747-xbrl.zip	Edgar Link	pending
atos-20200930.xml	Edgar Link	completed
atos-20200930.xsd	Edgar Link	pending
atos-20200930_cal.xml	Edgar Link	unprocessable
atos-20200930_def.xml	Edgar Link	unprocessable
atos-20200930_lab.xml	Edgar Link	unprocessable
atos-20200930_pre.xml	Edgar Link	unprocessable
atos20200930_10q.htm	Edgar Link	pending
ex_203415.htm	Edgar Link	pending
ex_203416.htm	Edgar Link	pending
ex_203417.htm	Edgar Link	pending
ex_203418.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos

2020 Q3 Form 10-Q Financial Statement

#000143774920023747 Filed on November 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS ATOSSA THERAPEUTICS, INC. Stock $atos

2020 Q3 Form 10-Q Financial Statement

#000143774920023747 Filed on November 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATOS
ATOSSA THERAPEUTICS, INC. Stock $atos